BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples